ArticleFrontiers in medicine2026
Identification of candidate selenium-associated transcriptomic biomarkers in chronic obstructive pulmonary disease: an integrated bioinformatics and expression validation study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic obstructive pulmonary disease (COPD) is marked by long-lasting airflow obstruction accompanied by persistent inflammation and disturbed redox balance. Although oxidative stress is well established in COPD, it remains unclear whether PBMC transcriptional patterns that co-vary with a curated selenium-metabolism and selenoprotein signature can identify candidate COPD markers. We therefore evaluated such patterns as an exploratory transcriptomic prioritization strategy rather than as evidence of selenium-specific regulation. Methods: COPD-related transcriptomic datasets were downloaded from the GEO database, and differentially expressed genes (DEGs) were determined using conventional differential expression analysis. Selenium metabolism and selenoprotein (SMASP) genes were collected from the MSigDB. WGCNA was then used to identify a module closely associated with COPD status and SMASP scores, and candidate genes were defined by intersecting module genes with DEGs. XGBoost and SVM-RFE, together with cross-validation, were applied to select biomarkers. A nomogram was subsequently generated to assess their diagnostic utility. Gene set enrichment analysis (GSEA) and RT-qPCR validation were finally conducted to examine the potential involvement of these biomarkers in COPD. Results: We detected 235 DEGs and 40 selenoprotein-related genes, from which 17 overlapping candidate genes were obtained. ERBB4 and ZKSCAN3 were ultimately retained as biomarkers and were significantly decreased in COPD samples. The nomogram based on these two genes showed favorable predictive ability. GSEA indicated that both biomarkers were associated with ribosome and olfactory transduction pathways. ERBB4 was also linked to neuroactive ligand-receptor interaction, whereas ZKSCAN3 was related to extracellular matrix (ECM)-receptor interaction. RT-qPCR in a small exploratory cohort ( Conclusion: ERBB4 and ZKSCAN3 were prioritized as exploratory candidate expression markers in the analyzed COPD datasets. Their diagnostic value, selenium specificity, and biological functions require confirmation in larger independent cohorts and functional studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.